BioWorld MedTech

April 14, 2014

New Boston Sci registry to evaluate Vercise DBS in Parkinson's patients

Boston Scientific (Natick, Massachusetts) has enrolled the first patient in a new registry to evaluate clinical outcomes and the economic value of the Vercise deep brain stimulation (DBS) system in patients with Parkinson's disease. Read More

Report from Israel: Nazareth incubator NGT3 raising funds with lofty dual agenda

Washington Roundup: FDA nod to Block HF adds 800K to market for biventricular pacing

MDD's Stock Watch

Report from Europe: Focus shifts from sales to costs for French startups

Court Report: Varian settles patent litigation with University of Pittsburgh for $35M

Deals Roundup: Covidien in plan to acquire New Wave Surgical for $100M

Report from Europe: Seno awarded CE mark for Imagio imaging system

Financings roundup: Ventas prices public offering of senior notes

Sebelius out at HHS, but Burwell unlikely to steer different course

People in Places

Briefly Noted

Product briefs

MDD's Neurology Extra

Today's news in brief

BioWorld

BioWorld briefs for May 22, 2026.

Acid alpha-glucosidase molecular structure isolated on black

‘Detargeted’ targeted gene therapy improves activity in Pompe

BioWorld

A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...

Sangamo presents primate data for prion suppressor ST-506

BioWorld Science

Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...

TREM2 agonists detailed in Pfizer patent

BioWorld Science

Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.

Roche reports new TREM2 agonists

BioWorld Science

F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...